The use of systemic and topical fluoroquinolones

Mary Anne Jackson; Gordon E. Schutze; Carrie L. Byington; Yvonne A. Maldonado; Elizabeth D. Barnett; James D. Campbell; H. Dele Davies; Ruth Lynfield; Flor M. Munoz; Dawn Nolt; Ann Christine Nyquist; Sean O'Leary; Mobeen H. Rathore; Mark H. Sawyer; William J. Steinbach; Tina Q. Tan; Theoklis E. Zaoutis; Committee on Infectious Diseases

doi:10.1542/peds.2016-2706

The use of systemic and topical fluoroquinolones

Mary Anne Jackson, Gordon E. Schutze, Carrie L. Byington, Yvonne A. Maldonado, Elizabeth D. Barnett, James D. Campbell, H. Dele Davies, Ruth Lynfield, Flor M. Munoz, Dawn Nolt, Ann Christine Nyquist, Sean O'Leary, Mobeen H. Rathore, Mark H. Sawyer, William J. Steinbach, Tina Q. Tan, Theoklis E. Zaoutis, Committee on Infectious Diseases

Pediatrics

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.

Original language	English (US)
Article number	e20162706
Journal	Pediatrics
Volume	138
Issue number	5
DOIs	https://doi.org/10.1542/peds.2016-2706
State	Published - Nov 2016

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1542/peds.2016-2706

Cite this

Jackson, M. A., Schutze, G. E., Byington, C. L., Maldonado, Y. A., Barnett, E. D., Campbell, J. D., Davies, H. D., Lynfield, R., Munoz, F. M., Nolt, D., Nyquist, A. C., O'Leary, S., Rathore, M. H., Sawyer, M. H., Steinbach, W. J., Tan, T. Q., Zaoutis, T. E., & Committee on Infectious Diseases (2016). The use of systemic and topical fluoroquinolones. Pediatrics, 138(5), Article e20162706. https://doi.org/10.1542/peds.2016-2706

@article{a2a7ee6e74a44a1fb3f403d38c1d694f,

title = "The use of systemic and topical fluoroquinolones",

abstract = "Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.",

author = "Jackson, {Mary Anne} and Schutze, {Gordon E.} and Byington, {Carrie L.} and Maldonado, {Yvonne A.} and Barnett, {Elizabeth D.} and Campbell, {James D.} and Davies, {H. Dele} and Ruth Lynfield and Munoz, {Flor M.} and Dawn Nolt and Nyquist, {Ann Christine} and Sean O'Leary and Rathore, {Mobeen H.} and Sawyer, {Mark H.} and Steinbach, {William J.} and Tan, {Tina Q.} and Zaoutis, {Theoklis E.} and {Committee on Infectious Diseases}",

note = "Publisher Copyright: Copyright {\textcopyright} 2016 by the American Academy of Pediatrics.",

year = "2016",

month = nov,

doi = "10.1542/peds.2016-2706",

language = "English (US)",

volume = "138",

journal = "Pediatrics",

issn = "0031-4005",

publisher = "American Academy of Pediatrics",

number = "5",

}

Jackson, MA, Schutze, GE, Byington, CL, Maldonado, YA, Barnett, ED, Campbell, JD, Davies, HD, Lynfield, R, Munoz, FM, Nolt, D, Nyquist, AC, O'Leary, S, Rathore, MH, Sawyer, MH, Steinbach, WJ, Tan, TQ, Zaoutis, TE & Committee on Infectious Diseases 2016, 'The use of systemic and topical fluoroquinolones', Pediatrics, vol. 138, no. 5, e20162706. https://doi.org/10.1542/peds.2016-2706

TY - JOUR

T1 - The use of systemic and topical fluoroquinolones

AU - Jackson, Mary Anne

AU - Schutze, Gordon E.

AU - Byington, Carrie L.

AU - Maldonado, Yvonne A.

AU - Barnett, Elizabeth D.

AU - Campbell, James D.

AU - Davies, H. Dele

AU - Lynfield, Ruth

AU - Munoz, Flor M.

AU - Nolt, Dawn

AU - Nyquist, Ann Christine

AU - O'Leary, Sean

AU - Rathore, Mobeen H.

AU - Sawyer, Mark H.

AU - Steinbach, William J.

AU - Tan, Tina Q.

AU - Zaoutis, Theoklis E.

AU - Committee on Infectious Diseases

PY - 2016/11

Y1 - 2016/11

N2 - Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.

AB - Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.

UR - http://www.scopus.com/inward/record.url?scp=84994885383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994885383&partnerID=8YFLogxK

U2 - 10.1542/peds.2016-2706

DO - 10.1542/peds.2016-2706

M3 - Article

C2 - 27940800

AN - SCOPUS:84994885383

SN - 0031-4005

VL - 138

JO - Pediatrics

JF - Pediatrics

IS - 5

M1 - e20162706

ER -

The use of systemic and topical fluoroquinolones

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this